We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Champions Oncology (CSBR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of CSBR and the rest of the Medical group's stocks.
Champions Oncology is a member of our Medical group, which includes 817 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CSBR is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CSBR's full-year earnings has moved 277.78% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, CSBR has moved about 209.02% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0.35%. This means that Champions Oncology is performing better than its sector in terms of year-to-date returns.
Looking more specifically, CSBR belongs to the Medical - Drugs industry, which includes 171 individual stocks and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have lost about 6.53% so far this year, so CSBR is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CSBR. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Champions Oncology (CSBR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of CSBR and the rest of the Medical group's stocks.
Champions Oncology is a member of our Medical group, which includes 817 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CSBR is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CSBR's full-year earnings has moved 277.78% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, CSBR has moved about 209.02% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0.35%. This means that Champions Oncology is performing better than its sector in terms of year-to-date returns.
Looking more specifically, CSBR belongs to the Medical - Drugs industry, which includes 171 individual stocks and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have lost about 6.53% so far this year, so CSBR is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CSBR. The stock will be looking to continue its solid performance.